NCI-H460细胞

NCI-H460/NCI-H460细胞系/NCI-H460细胞株/NCI-H460人大细胞肺癌细胞

Cell line name NCI-H460

Synonyms NCI.H460; H460; H-460; NCIH460; NCI-HUT-460; NCI-460

Accession CVCL_0459

Resource Identification Initiative To cite this cell line use: NCI-H460 (RRID:CVCL_0459)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).

Part of: JFCR39 cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Population: Caucasian.

Characteristics: Expresses HPRT1 at the surface of the cell membrane (PubMed=28408844).

Doubling time: 33 hours (Note=In RPMI 1640 + 10% FBS), 60 hours (Note=In ACL-3), 42 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 19 hours (PubMed=7718330); 0.8 days (PubMed=11551417); 21.5 hours (PubMed=29681454); 18.39 +- 1.35 hours (PubMed=33425914); ~23 hours (DSMZ=ACC-737); 17.8 hours (NCI-DTP=NCI-H460).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Fluorescence phenotype profiling.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.

PubMed=1563005

Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.

Neuromedin B is present in lung cancer cell lines.

Cancer Res. 52:2732s-2736s(1992)

 

PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x; PMCID=PMC5919128

Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y., Takahashi T., Ueda R.

Alterations of integrin expression in human lung cancer.

Jpn. J. Cancer Res. 84:168-174(1993)

 

PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H

Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.L.

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

Eur. J. Cancer 31A:230-237(1995)

 

PubMed=8626706; DOI=10.1074/jbc.271.19.11477

Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F.

Insulin-like growth factor expression in human cancer cell lines.

J. Biol. Chem. 271:11477-11483(1996)

 

PubMed=8806092; DOI=10.1002/jcb.240630505

Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

NCI-Navy Medical Oncology Branch cell line data base.

J. Cell. Biochem. Suppl. 24:32-91(1996)

 

PubMed=10358721; DOI=10.18926/AMO/31626

Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K., Kohara H., Harada M.

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Acta Med. Okayama 53:67-75(1999)

 

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

 

PubMed=11030152; DOI=10.1038/sj.onc.1203815

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Oncogene 19:4632-4639(2000)

 

PubMed=11551417; DOI=10.1016/S0169-5002(01)00205-7

Yoon S.-S., Ahn K.-S., Kim S.-H., Shim Y.M., Kim J.

In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype.

Lung Cancer 33:221-228(2001)

 

PubMed=11583962; DOI=10.1016/S0002-9440(10)62521-7; PMCID=PMC1850523

Haruki N., Harano T., Masuda A., Kiyono T., Takahashi T., Tatematsu Y., Shimizu S., Mitsudomi T., Konishi H., Osada H., Fujii Y., Takahashi T.

Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation.

Am. J. Pathol. 159:1345-1352(2001)